Clinical Trial Update: Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing OctaAlpha1 to Glassia for Alpha-1 antitrypsin deficiency has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)
• OctaAlpha1

Snippet

Sponsor: Octapharma | Conditions: Alpha 1-Antitrypsin Deficiency | Phase 2 | Status: WITHDRAWN